Literature DB >> 19625288

Clinical evaluation of NucliSENS magnetic extraction and NucliSENS analytical specific reagents for the real-time detection of respiratory syncytial virus (RSV) in paediatric respiratory specimens.

R Manji1, M Lotlikar, F Zhang, C C Ginocchio.   

Abstract

AIMS: To evaluate the combination of NucliSENS magnetic extraction and NucliSENS analytical specific reagents (bioMérieux, Marcy L'Etoile, France) for the detection of respiratory syncytial virus (RSV) from a variety of respiratory samples.
METHODS: Nucleic acids (NA) from paediatric samples (n = 603) and an RSV-specific inhibition control (R-IC) were coextracted using the miniMAG and/or the easyMAG. Nucleic-acid-sequence-based amplification (NASBA) and molecular beacon detection of RSV and R-IC were performed using NucliSENS analyte-specific reagents (NRSVA) and the NucliSENS EasyQ Analyzer. NRSVA results were compared with R-Mix culture and direct fluorescent antibody detection (DFA).
RESULTS: The NRSVA analytical specificity was 100%, and the NRSVA limit of detection was 5-20 RNA copies/reaction. The prediscordant analysis, sensitivity, specificity, PPV and NPV were, respectively, for R-Mix (64.7%, 100%, 100%, 94.5%); DFA (98.8%, 99.0%, 94.4%, 99.8%); NRSVA (94.1%, 95%, 75.5%, 99%). After discordant analysis, sensitivity, specificity, PPV and NPV were, respectively, for R-Mix (56.7%, 100%, 100%, 92.3%); DFA (87.6%, 99.2%, 95.5%, 97.7%); NRSVA (93.8%, 97%, 85.9%, 99%). RSV was detected in 17.8% of the samples and in seven coinfections. Children with proven RSV infection, compared with children without a pathogen identified, had shorter median hospitalisation stays (2 days vs 3 days, p = 0.035), used fewer antibiotics (54% vs 69%) and had shorter durations of antibiotic therapy (6.2 days vs 9.3 days, p = 0.021), respectively.
CONCLUSIONS: NRSVA is sensitive and specific for RSV detection in respiratory samples. The R-IC monitored the test process, including NA extraction, target amplification and detection. The rapid detection of respiratory pathogens can foster appropriate patient management.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19625288     DOI: 10.1136/jcp.2009.066688

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  6 in total

1.  Development of a sensitive loop-mediated isothermal amplification assay that provides specimen-to-result diagnosis of respiratory syncytial virus infection in 30 minutes.

Authors:  James Mahony; Sylvia Chong; David Bulir; Alexandra Ruyter; Ken Mwawasi; Daniel Waltho
Journal:  J Clin Microbiol       Date:  2013-06-12       Impact factor: 5.948

2.  Advances in diagnosis of respiratory virus infections.

Authors:  Michael Loeffelholz; Tasnee Chonmaitree
Journal:  Int J Microbiol       Date:  2010-10-19

3.  Molecular beacons in diagnostics.

Authors:  Sanjay Tyagi; Fred Russell Kramer
Journal:  F1000 Med Rep       Date:  2012-05-02

Review 4.  Alternative molecular tests for virological diagnosis.

Authors:  Francesca Sidoti; Massimiliano Bergallo; Cristina Costa; Rossana Cavallo
Journal:  Mol Biotechnol       Date:  2013-03       Impact factor: 2.695

5.  Strengths and weaknesses of FDA-approved/cleared diagnostic devices for the molecular detection of respiratory pathogens.

Authors:  Christine C Ginocchio
Journal:  Clin Infect Dis       Date:  2011-05       Impact factor: 9.079

6.  Infant deaths from respiratory syncytial virus in Lusaka, Zambia from the ZPRIME study: a 3-year, systematic, post-mortem surveillance project.

Authors:  Christopher J Gill; Lawrence Mwananyanda; William B MacLeod; Geoffrey Kwenda; Rachel Pieciak; Zachariah Mupila; Caitriona Murphy; Chilufya Chikoti; Leah Forman; Flora Berklein; Rotem Lapidot; Charles Chimoga; Benard Ngoma; Anna Larson; James Lungu; Ruth Nakazwe; Diana Nzara; Lillian Pemba; Baron Yankonde; Angel Chirwa; Magda Mwale; Donald M Thea
Journal:  Lancet Glob Health       Date:  2022-02       Impact factor: 26.763

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.